Endo International plc
Glandore Business Centres
No. 33 Fitzwilliam Square
Dublin 2
Tel: 353-1-669-8559 or 800-462-3636
Fax: 800-329-3636
Website: http://www.endo.com/
311 articles about Endo International plc
-
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
3/26/2024
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
-
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
3/12/2024
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level.
-
Endo Reports Fourth-Quarter 2023 Financial Results
3/6/2024
Endo International plc reported financial results for the fourth-quarter ended December 31, 2023.
-
Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open
1/24/2024
Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study.
-
Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting
1/19/2024
Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX ® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.
-
Endo Announces Five Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting
11/16/2023
Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in San Diego.
-
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
9/21/2023
Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Orthopaedic Foot & Ankle Society's (AOFAS) annual scientific meeting.
-
ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS
8/8/2023
Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023.
-
Endo Announces First Patient Enrolled in Registry of Peyronie's Disease
7/20/2023
Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie's disease), a non-interventional registry of up to 1,000 patients with Peyronie's disease (PD).
-
Endo Launches Bivalirudin Injection in Ready-to-Use Vials
7/18/2023
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial.
-
Endo and Premier, Inc. Collaborate to Address Pitocin® (oxytocin injection, USP) Shortage
7/17/2023
Endo International plc and Premier, Inc. announced that Endo's Par Sterile Products business will supply Pitocin® vials through Premier's ProvideGx® and PremierProRx® programs.
-
Endo Presents New Data at the American Podiatric Medical Association Annual Meeting
7/13/2023
Endo International plc (OTC: ENDPQ) announced today that new data from a Phase 1 study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Podiatric Medical Association's (APMA) annual scientific meeting.
-
Endo Launches First Generic Version of Noxafil® (posaconazole) Injection
6/29/2023
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's Noxafil® in the U.S., following final approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application.
-
Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada
6/29/2023
Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI ™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
-
Endo Announces First Patient Enrolled in Registry of Dupuytren's Contracture
6/26/2023
Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC).
-
Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant®
6/15/2023
Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping dexlansoprazole 30 mg capsules, a generic version of Takeda's Dexilant®.
-
C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation
6/12/2023
C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc, have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia patients in Canada.
-
Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe
6/12/2023
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S.
-
Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®
6/5/2023
Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) in treating men with Peyronie's disease (PD) were published by peer-reviewed journal Urology ®.
-
Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials
5/24/2023
Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial in the U.S. Endo will commercialize the FDA-approved product through its Par Sterile Products business and expects to begin shipping in summer 2023.